Skip to main content
Premium Trial:

Request an Annual Quote

Corning and Promega Create Microarray Reagents Deal Targeting Home Brew Market

Premium

Corning this week announced a new microarray initiative in collaboration with Promega of Madison, Wis.

The two companies will develop and manufacture an integrated set of slides and reagents for the home-brew microarray market, which will be marketed as Pronto Plus Systems.

The strategic alliance follows the glass-slide maker’s entry into the microarray reagent market with a system for validation, printing, and hybridization. This system will be combined with Promega products including SV Total RNA Isolation, ChipShot labeling, and ChipShot cleanup.

A Market Re-entry?

The announcement is surprising given Corning’s history in microarray manufacturing. Citing market conditions in 2001, the company exited a one-year microarray venture, Corning Microarray Technologies, which was based on its cata-lytic converter technology, its Pyrex lab glass, and its flat panel display glass.

However, the company has continued to market its gamma-amino-propyl-silane (GAPS) coated glass slides for arrays, and maintain funding for a $10 million four-year research collaboration with MIT’s Whitehead Institute for Biomedical Research.

The companies are marketing the Pronto products in the following six kits:

Systems 1 and 2 ($545-$599) are for core facilities or printing groups wishing to validate Pronto Reagents from microarray manufacturing to hybridization; Systems 3 and 5 ($380-$435) are designed for researchers who will purify total RNA, generate labeled cDNA and hybridize to microarrays printed on Corning’s UltraGAPS slides; while Systems 4 and 6 ($950-$ 1,095) are configured for microarray researchers who obtain purified total RNA and need only to label cDNA and hybridize to DNA microarrays printed on UltraGAPS glass slides.

— MOK

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.